Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.74 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536562 | 1.00 | AR (0.74) | ARCRBN | |
| SCHEMBL24266797 | 1.00 | AR (0.74) | ARCRBN | |
| SCHEMBL31061198 | 0.93 | AR (0.73) | ARCRBN | |
| SCHEMBL22197929 | 0.93 | AR (0.73) | ARCRBN | |
| SCHEMBL17519965 | 0.90 | AR (0.73) | ARCRBN | |
| SCHEMBL18473049 | 0.90 | AR (0.73) | ARCRBN | |
| SCHEMBL17941080 | 0.90 | AR (0.73) | ARCRBN | |
| SCHEMBL17523083 | 0.90 | AR (0.73) | ARCRBN | |
| SCHEMBL17519966 | 0.90 | AR (0.73) | ARCRBN | |
| SCHEMBL25315777 | 0.89 | AR (0.72) | ARCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220162163-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2018144649-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas, Inc. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2017011371-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS, INC (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | AR 3776/4885CRBN 1/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | AR 3905/4885CRBN 1/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | AR 799/4885CRBN 1/4885 |
| US-20180169109-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | AR 1198/4885CRBN 97/4885 |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | AR 1479/4885CRBN 1160/4885 |
| US-20180179522-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | AR 3743/4885CRBN 138/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | AR 1479/4885CRBN 1160/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | AR 1169/4885CRBN 92/4885 |
| US-20220162163-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | AR 2932/4885CRBN 483/4885 |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | AR 2687/4885CRBN 43/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | AR 799/4885CRBN 1/4885 |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | AR 2454/4885CRBN 148/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | AR 1169/4885CRBN 92/4885 |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | AR 2932/4885CRBN 483/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | AR 3776/4885CRBN 1/4885 |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | AR 996/4885CRBN 176/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | AR 3905/4885CRBN 1/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | AR 3743/4885CRBN 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.